QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's Pivotal Study and its implications for the BLA submission timeline [2][4]. Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA's approval of the Pivotal Study design [4]. - It is claimed that the company downplayed the likelihood of needing to delay its BLA submission due to additional studies required by the FDA [4]. - The statements made by the defendants about the company's business and prospects are said to lack a reasonable basis [4]. Group 2: Impact of Recent Disclosures - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would support a BLA submission, leading to uncertainty about the submission timeline [5]. - Following this announcement, uniQure's share price fell by $33.40, a decline of over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [6]. Group 3: Legal Proceedings - Investors who purchased uniQure securities between September 24, 2025, and October 31, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options, with a deadline of April 13, 2026, to seek the role of lead plaintiff in the class action [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [7]. Group 4: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].